Long-Term Follow-Up of Choroidal Neovascularization due to Angioid Streaks with pro re nata Intravitreal Anti-VEGF Treatment

Giovanni Giacomelli, Lucia Finocchio, Ilaria Biagini, Andrea Sodi, Vittoria Murro, Ugo Introini, Monica Varano, Francesco Bandello, Ugo Menchini

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: To evaluate the long-term outcomes of intravitreal anti-vascular endothelial growth factor (VEGF) drugs with a pro re nata (PRN) regimen for the treatment of choroidal neovascularization (CNV) secondary to angioid streaks (AS). Methods: This is a retrospective, multicenter, noncomparative case series of consecutive AS eyes affected by treatment-naïve CNV. A complete ophthalmologic examination was performed every 30-45 days after the loading phase, including fluorescein angiography and/or optical coherence tomography. Results: In all, 52 eyes of 39 patients were treated with intravitreal bevacizumab and/or ranibizumab and followed up for a mean of 33.8 months. The best corrected visual acuity at baseline was 20/40, and it deteriorated by an average of 6.8 ETDRS letters per year (p < 0.001). We performed an average of 5.1, 6.5, and 6.8 injections at the 1-, 2-, and 3-year follow-up, respectively. Conclusions: Intravitreal anti-VEGF drugs in a PRN regimen with close monitoring appear to slow the progression of CNV in AS, but they do not prevent the affected eyes from progressive visual loss.

Original languageEnglish
Pages (from-to)44-51
Number of pages8
JournalOphthalmologica
Volume238
Issue number1-2
DOIs
Publication statusPublished - 2017

Fingerprint

Angioid Streaks
Choroidal Neovascularization
Vascular Endothelial Growth Factor A
Fluorescein Angiography
Optical Coherence Tomography
Pharmaceutical Preparations
Visual Acuity
Therapeutics
Injections

Keywords

  • Anti-vascular endothelial growth factor treatment
  • Macular diseases
  • Neovascular membranes

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Cite this

Giacomelli, G., Finocchio, L., Biagini, I., Sodi, A., Murro, V., Introini, U., ... Menchini, U. (2017). Long-Term Follow-Up of Choroidal Neovascularization due to Angioid Streaks with pro re nata Intravitreal Anti-VEGF Treatment. Ophthalmologica, 238(1-2), 44-51. https://doi.org/10.1159/000477498

Long-Term Follow-Up of Choroidal Neovascularization due to Angioid Streaks with pro re nata Intravitreal Anti-VEGF Treatment. / Giacomelli, Giovanni; Finocchio, Lucia; Biagini, Ilaria; Sodi, Andrea; Murro, Vittoria; Introini, Ugo; Varano, Monica; Bandello, Francesco; Menchini, Ugo.

In: Ophthalmologica, Vol. 238, No. 1-2, 2017, p. 44-51.

Research output: Contribution to journalArticle

Giacomelli, Giovanni ; Finocchio, Lucia ; Biagini, Ilaria ; Sodi, Andrea ; Murro, Vittoria ; Introini, Ugo ; Varano, Monica ; Bandello, Francesco ; Menchini, Ugo. / Long-Term Follow-Up of Choroidal Neovascularization due to Angioid Streaks with pro re nata Intravitreal Anti-VEGF Treatment. In: Ophthalmologica. 2017 ; Vol. 238, No. 1-2. pp. 44-51.
@article{10fe5c898b3e440fb5dabdc2a75f5da4,
title = "Long-Term Follow-Up of Choroidal Neovascularization due to Angioid Streaks with pro re nata Intravitreal Anti-VEGF Treatment",
abstract = "Purpose: To evaluate the long-term outcomes of intravitreal anti-vascular endothelial growth factor (VEGF) drugs with a pro re nata (PRN) regimen for the treatment of choroidal neovascularization (CNV) secondary to angioid streaks (AS). Methods: This is a retrospective, multicenter, noncomparative case series of consecutive AS eyes affected by treatment-na{\"i}ve CNV. A complete ophthalmologic examination was performed every 30-45 days after the loading phase, including fluorescein angiography and/or optical coherence tomography. Results: In all, 52 eyes of 39 patients were treated with intravitreal bevacizumab and/or ranibizumab and followed up for a mean of 33.8 months. The best corrected visual acuity at baseline was 20/40, and it deteriorated by an average of 6.8 ETDRS letters per year (p < 0.001). We performed an average of 5.1, 6.5, and 6.8 injections at the 1-, 2-, and 3-year follow-up, respectively. Conclusions: Intravitreal anti-VEGF drugs in a PRN regimen with close monitoring appear to slow the progression of CNV in AS, but they do not prevent the affected eyes from progressive visual loss.",
keywords = "Anti-vascular endothelial growth factor treatment, Macular diseases, Neovascular membranes",
author = "Giovanni Giacomelli and Lucia Finocchio and Ilaria Biagini and Andrea Sodi and Vittoria Murro and Ugo Introini and Monica Varano and Francesco Bandello and Ugo Menchini",
year = "2017",
doi = "10.1159/000477498",
language = "English",
volume = "238",
pages = "44--51",
journal = "Ophthalmologica",
issn = "0030-3755",
publisher = "S. Karger AG",
number = "1-2",

}

TY - JOUR

T1 - Long-Term Follow-Up of Choroidal Neovascularization due to Angioid Streaks with pro re nata Intravitreal Anti-VEGF Treatment

AU - Giacomelli, Giovanni

AU - Finocchio, Lucia

AU - Biagini, Ilaria

AU - Sodi, Andrea

AU - Murro, Vittoria

AU - Introini, Ugo

AU - Varano, Monica

AU - Bandello, Francesco

AU - Menchini, Ugo

PY - 2017

Y1 - 2017

N2 - Purpose: To evaluate the long-term outcomes of intravitreal anti-vascular endothelial growth factor (VEGF) drugs with a pro re nata (PRN) regimen for the treatment of choroidal neovascularization (CNV) secondary to angioid streaks (AS). Methods: This is a retrospective, multicenter, noncomparative case series of consecutive AS eyes affected by treatment-naïve CNV. A complete ophthalmologic examination was performed every 30-45 days after the loading phase, including fluorescein angiography and/or optical coherence tomography. Results: In all, 52 eyes of 39 patients were treated with intravitreal bevacizumab and/or ranibizumab and followed up for a mean of 33.8 months. The best corrected visual acuity at baseline was 20/40, and it deteriorated by an average of 6.8 ETDRS letters per year (p < 0.001). We performed an average of 5.1, 6.5, and 6.8 injections at the 1-, 2-, and 3-year follow-up, respectively. Conclusions: Intravitreal anti-VEGF drugs in a PRN regimen with close monitoring appear to slow the progression of CNV in AS, but they do not prevent the affected eyes from progressive visual loss.

AB - Purpose: To evaluate the long-term outcomes of intravitreal anti-vascular endothelial growth factor (VEGF) drugs with a pro re nata (PRN) regimen for the treatment of choroidal neovascularization (CNV) secondary to angioid streaks (AS). Methods: This is a retrospective, multicenter, noncomparative case series of consecutive AS eyes affected by treatment-naïve CNV. A complete ophthalmologic examination was performed every 30-45 days after the loading phase, including fluorescein angiography and/or optical coherence tomography. Results: In all, 52 eyes of 39 patients were treated with intravitreal bevacizumab and/or ranibizumab and followed up for a mean of 33.8 months. The best corrected visual acuity at baseline was 20/40, and it deteriorated by an average of 6.8 ETDRS letters per year (p < 0.001). We performed an average of 5.1, 6.5, and 6.8 injections at the 1-, 2-, and 3-year follow-up, respectively. Conclusions: Intravitreal anti-VEGF drugs in a PRN regimen with close monitoring appear to slow the progression of CNV in AS, but they do not prevent the affected eyes from progressive visual loss.

KW - Anti-vascular endothelial growth factor treatment

KW - Macular diseases

KW - Neovascular membranes

UR - http://www.scopus.com/inward/record.url?scp=85021153958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021153958&partnerID=8YFLogxK

U2 - 10.1159/000477498

DO - 10.1159/000477498

M3 - Article

VL - 238

SP - 44

EP - 51

JO - Ophthalmologica

JF - Ophthalmologica

SN - 0030-3755

IS - 1-2

ER -